Join today and have your say! It’s FREE!
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by Oden6570on Feb 10, 2024 6:00am
351 Views
Post# 35873575

Brain Tumor Research |

Brain Tumor Research |An important new clinical trial, which will be the first in the U.S. for newly diagnosed GBM patients, will be intraoperative photodynamic therapy (PDT). Patients will initially undergo a maximal resection of their GBM tumor with the use of 5-ALA fluorescence-guided surgery (FGS). After completion of tumor removal during surgery, intraoperative 5-ALA PDT will then be performed. Patients will then go onto their standard of care treatment options after their tumor removal and PDT. Enrollment of the first GBM patients will occur in late 2023, with Jan Drappatz, MD, associate director of neuro-oncology at UPMC, serving as the principal investigator. 
Brain Tumor Research | University of Pittsburgh
<< Previous
Bullboard Posts
Next >>